Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.64 |
| ▸ | ECE1 | P42892 | 12/20 | 0.59 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | APAF1 | O14727 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21641793 | 0.93 | ACE (0.73) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL29380886 | 0.93 | ACE (0.73) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL21641792 | 0.93 | ACE (0.73) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL21641791 | 0.93 | ACE (0.73) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL29492470 | 0.91 | ACE (0.62) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL30834726 | 0.91 | ACE (0.66) | ACEECE1ERAP2 | |
| SCHEMBL32681291 | 0.91 | ERAP2 (0.68) | ACEECE1ERAP2 | |
| SCHEMBL31720550 | 0.91 | ACE (0.69) | ACEECE1 | |
| SCHEMBL30834729 | 0.90 | ACE (0.61) | ACEECE1ERAP2ALOX15 | |
| SCHEMBL30567428 | 0.90 | ACE (0.61) | ACEECE1ERAP2KDM4EAPAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2025-11-06 | — | — | US | disclosed |
| EP-4448544-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B Pharmaceuticals GmbH (DE) | 2024-10-23 | — | — | EP | disclosed |
| WO-2023111350-A2 | CARBONIC ANHYDRASE IX LIGANDS | 3B PHARMACEUTICALS GMBH (DE) | 2023-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339569-A1 | CARBONIC ANHYDRASE IX LIGANDS | CA9, CA13, CA4 | ACE 760/4885ECE1 1288/4885ERAP2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.